57 related articles for article (PubMed ID: 14697138)
21. A CIITA-independent pathway that promotes expression of endogenous rather than exogenous peptides in immune-privileged sites.
Arancibia-Cárcamo CV; Osawa H; Arnett HA; Háskova Z; George AJ; Ono SJ; Ting JP; Streilein JW
Eur J Immunol; 2004 Feb; 34(2):471-80. PubMed ID: 14768052
[TBL] [Abstract][Full Text] [Related]
22. Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes.
LeibundGut-Landmann S; Waldburger JM; Krawczyk M; Otten LA; Suter T; Fontana A; Acha-Orbea H; Reith W
Eur J Immunol; 2004 Jun; 34(6):1513-25. PubMed ID: 15162420
[TBL] [Abstract][Full Text] [Related]
23. Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA).
Takamura Y; Ikeda H; Kanaseki T; Toyota M; Tokino T; Imai K; Houkin K; Sato N
Glia; 2004 Mar; 45(4):392-405. PubMed ID: 14966870
[TBL] [Abstract][Full Text] [Related]
24. [Biological activity of C II TA anti-sense RNA--a novel approach to inhibition of rejection in transplantation].
Guo R; Zou P; Du X; Zhag M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):848-51. PubMed ID: 16277856
[TBL] [Abstract][Full Text] [Related]
25. Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor.
Mueller RB; Skapenko A; Grunke M; Wendler J; Stuhlmuller B; Kalden JR; Schulze-Koops H
Arthritis Rheum; 2005 Feb; 52(2):451-60. PubMed ID: 15692975
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator.
Radosevich M; Jager M; Ono SJ
Exp Mol Pathol; 2007 Feb; 82(1):68-76. PubMed ID: 16650406
[TBL] [Abstract][Full Text] [Related]
27. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
[TBL] [Abstract][Full Text] [Related]
28. Attenuation of allograft rejection by intragraft inhibition of class II transcativator in high responder rat liver transplantation.
Liu G; He X; Lu N; Qiu Y; Wang H
Microsurgery; 2015 Jan; 35(1):52-9. PubMed ID: 24764281
[TBL] [Abstract][Full Text] [Related]
29. Hexim1 sequesters positive transcription elongation factor b from the class II transactivator on MHC class II promoters.
Kohoutek J; Blazek D; Peterlin BM
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17349-54. PubMed ID: 17088550
[TBL] [Abstract][Full Text] [Related]
30. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
31. Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription Implication of CIITA in tumor and metastasis development.
Shi B; Vinyals A; Alia P; Broceño C; Chen F; Adrover M; Gelpi C; Price JE; Fabra A
Int J Biochem Cell Biol; 2006; 38(4):544-62. PubMed ID: 16343978
[TBL] [Abstract][Full Text] [Related]
32. CIITA transformation rescues the apoptotic function of MHC class II in melanoma cells.
Le E; Zhang H; Blanck G
Anticancer Res; 2005; 25(6B):3889-92. PubMed ID: 16312044
[TBL] [Abstract][Full Text] [Related]
33. Tumor-mediated down-regulation of MHC class II in DC development is attributable to the epigenetic control of the CIITA type I promoter.
Choi YE; Yu HN; Yoon CH; Bae YS
Eur J Immunol; 2009 Mar; 39(3):858-68. PubMed ID: 19224634
[TBL] [Abstract][Full Text] [Related]
34. Pathologic expression of MHC class II is driven by mitogen-activated protein kinases.
Martins I; Deshayes F; Baton F; Forget A; Ciechomska I; Sylla K; Aoudjit F; Charron D; Al-Daccak R; Alcaide-Loridan C
Eur J Immunol; 2007 Mar; 37(3):788-97. PubMed ID: 17304627
[TBL] [Abstract][Full Text] [Related]
35. Constitutive and IFNgamma-induced activation of MHC2TA promoter type III in human melanoma cell lines is governed by separate regulatory elements within the PIII upstream regulatory region.
van der Stoep N; Quinten E; Alblas G; Plancke A; van Eggermond MC; Holling TM; van den Elsen PJ
Mol Immunol; 2007 Mar; 44(8):2036-46. PubMed ID: 17067677
[TBL] [Abstract][Full Text] [Related]
36. T cell expression of CIITA represses Th1 immunity.
Park WS; Bae Y; Chung DH; Choi YL; Kim BK; Sung YC; Choi EY; Park SH; Jung KC
Int Immunol; 2004 Oct; 16(10):1355-64. PubMed ID: 15351782
[TBL] [Abstract][Full Text] [Related]
37. In vitro biological activity of anti-C II TA hammerhead ribozyme--a novel approach for autoimmune diseases.
Liu F; Zou P; Guo R; Lu H; Fan H
J Huazhong Univ Sci Technolog Med Sci; 2003; 23(4):335-8. PubMed ID: 15015629
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic regulation of MHC-II and CIITA genes.
Wright KL; Ting JP
Trends Immunol; 2006 Sep; 27(9):405-12. PubMed ID: 16870508
[TBL] [Abstract][Full Text] [Related]
39. MHC Class II alleles in ulcerative colitis-associated colorectal cancer.
Garrity-Park MM; Loftus EV; Sandborn WJ; Bryant SC; Smyrk TC
Gut; 2009 Sep; 58(9):1226-33. PubMed ID: 19251712
[TBL] [Abstract][Full Text] [Related]
40. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition.
Berghuis D; de Hooge AS; Santos SJ; Horst D; Wiertz EJ; van Eggermond MC; van den Elsen PJ; Taminiau AH; Ottaviano L; Schaefer KL; Dirksen U; Hooijberg E; Mulder A; Melief CJ; Egeler RM; Schilham MW; Jordanova ES; Hogendoorn PC; Lankester AC
J Pathol; 2009 Jun; 218(2):222-31. PubMed ID: 19274709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
